Research Lab Director, Molecular Modeling & Drug Discovery Lab
Istituto Italiano di Tecnologia
CDC42 RHOJ Interaction Inhibitors for the Treatment of Neurofibromatosis
Neurofibromatosis type 2 (NF2) tumors can cause significant hearing loss and current therapies can accelerate this loss through the impact of side effects and non compliance. Using cell lines provided by the Children’s Brain Tumor Network, researchers are testing new treatments to address this issue.